BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment and Enhancing Access


Share

Program Content

Activities

  • Immunotherapy in MM
    Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 17, 2024

    Expires: May 16, 2025

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme